209 related articles for article (PubMed ID: 36266272)
21.
Maity PC; Bilal M; Koning MT; Young M; van Bergen CAM; Renna V; Nicolò A; Datta M; Gentner-Göbel E; Barendse RS; Somers SF; de Groen RAL; Vermaat JSP; Steinbrecher D; Schneider C; Tausch E; Bittolo T; Bomben R; Mazzarello AN; Del Poeta G; Kroes WGM; van Wezel JT; Imkeller K; Busse CE; Degano M; Bakchoul T; Schulz AR; Mei H; Ghia P; Kotta K; Stamatopoulos K; Wardemann H; Zucchetto A; Chiorazzi N; Gattei V; Stilgenbauer S; Veelken H; Jumaa H
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4320-4327. PubMed ID: 32047037
[TBL] [Abstract][Full Text] [Related]
22. Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.
Pal Singh S; de Bruijn MJW; de Almeida MP; Meijers RWJ; Nitschke L; Langerak AW; Pillai SY; Stadhouders R; Hendriks RW
Front Immunol; 2018; 9():1996. PubMed ID: 30271400
[TBL] [Abstract][Full Text] [Related]
23. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia.
Huang PY; Mactier S; Armacki N; Giles Best O; Belov L; Kaufman KL; Pascovici D; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2016 May; 57(5):1033-43. PubMed ID: 26422656
[TBL] [Abstract][Full Text] [Related]
24. The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.
Stevenson FK; Forconi F; Packham G
Semin Hematol; 2014 Jul; 51(3):158-67. PubMed ID: 25048780
[TBL] [Abstract][Full Text] [Related]
25. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
26. Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen.
Kashuba E; Eagle GL; Bailey J; Evans P; Welham KJ; Allsup D; Cawkwell L
J Proteomics; 2013 Oct; 91():478-85. PubMed ID: 23938224
[TBL] [Abstract][Full Text] [Related]
27. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
28. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
29. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia.
Ferreira PG; Jares P; Rico D; Gómez-López G; Martínez-Trillos A; Villamor N; Ecker S; González-Pérez A; Knowles DG; Monlong J; Johnson R; Quesada V; Djebali S; Papasaikas P; López-Guerra M; Colomer D; Royo C; Cazorla M; Pinyol M; Clot G; Aymerich M; Rozman M; Kulis M; Tamborero D; Gouin A; Blanc J; Gut M; Gut I; Puente XS; Pisano DG; Martin-Subero JI; López-Bigas N; López-Guillermo A; Valencia A; López-Otín C; Campo E; Guigó R
Genome Res; 2014 Feb; 24(2):212-26. PubMed ID: 24265505
[TBL] [Abstract][Full Text] [Related]
30. Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.
Johnston HE; Carter MJ; Larrayoz M; Clarke J; Garbis SD; Oscier D; Strefford JC; Steele AJ; Walewska R; Cragg MS
Mol Cell Proteomics; 2018 Apr; 17(4):776-791. PubMed ID: 29367434
[TBL] [Abstract][Full Text] [Related]
31. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.
Griffen TL; Hoff FW; Qiu Y; Lillard JW; Ferrajoli A; Thompson P; Toro E; Ruiz K; Burger J; Wierda W; Kornblau SM
Blood Cancer J; 2022 Mar; 12(3):43. PubMed ID: 35301276
[TBL] [Abstract][Full Text] [Related]
32. Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study.
Stranska K; Plevova K; Skuhrova Francova H; Skabrahova H; von Jagwitz-Biegnitz M; Radova L; Panovska A; Hrobkova S; Brychtova Y; Urbanova R; Smolej L; Simkovic M; Zuchnicka J; Mohammadova L; Spacek M; Mayer J; Pospisilova S; Doubek M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Dec; 164(4):425-434. PubMed ID: 31558845
[TBL] [Abstract][Full Text] [Related]
33. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
[TBL] [Abstract][Full Text] [Related]
34. Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes.
Cochran DA; Evans CA; Blinco D; Burthem J; Stevenson FK; Gaskell SJ; Whetton AD
Mol Cell Proteomics; 2003 Dec; 2(12):1331-41. PubMed ID: 14557598
[TBL] [Abstract][Full Text] [Related]
35. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E
Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804
[TBL] [Abstract][Full Text] [Related]
36. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
37. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
von Wenserski L; Schultheiß C; Bolz S; Schliffke S; Simnica D; Willscher E; Gerull H; Wolters-Eisfeld G; Riecken K; Fehse B; Altfeld M; Nollau P; Binder M
Leukemia; 2021 Apr; 35(4):1073-1086. PubMed ID: 32826957
[TBL] [Abstract][Full Text] [Related]
38. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
39. Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia.
Alsagaby SA; Khanna S; Hart KW; Pratt G; Fegan C; Pepper C; Brewis IA; Brennan P
J Proteome Res; 2014 Nov; 13(11):5051-62. PubMed ID: 24983324
[TBL] [Abstract][Full Text] [Related]
40. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
Dal Bo M; Bulian P; Bomben R; Zucchetto A; Rossi FM; Pozzo F; Tissino E; Benedetti D; Bittolo T; Nanni P; Cattarossi I; Zaina E; Chivilò H; Degan M; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Principe MI; Del Poeta G; Rossi D; Gaidano G; Gattei V
Leukemia; 2016 Oct; 30(10):2011-2018. PubMed ID: 27109509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
